Car T-Cell Therapy Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 30.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Car T-Cell Therapy Market Analysis
The CAR T-cell therapy market is expected to register a CAGR of more than 30% over the forecast period.
The COVID-19 pandemic has significantly impacted the CAR T-cell therapy market. As per an article published in November 2021 in PubMed, CAR T-cell therapy recipients were believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state caused by prior lymphodepletion immunochemotherapy and CAR-T-cell therapy-related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. Such studies reflect that the onset of the COVID-19 pandemic reduced the number of patients undergoing CAR-T cell therapy, significantly impacting the demand for CAR-T-cell therapy. However, with the introduction of vaccines and uplifting lockdown restrictions, research and development activities have been resumed, and patient visits increased, reflecting that the market is expected to grow significantly in the coming period.
The market's growth can be attributed to the factors such as the increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy. For instance, according to the Macmillan Cancer Support statistics updated in October 2022, the estimated number of people currently living with cancer in the UK are likely to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This estimation includes 1,010,310 number of males and 948,000 cases of females. Furthermore, as per a June 2021 update by the American Society of Clinical Oncology (ASCO), cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists can make T cells better equipped to find and kill some cancer cells. Thus, the anticipated increase in cancer cases will drive the demand for CAR T-cell therapy in the coming period. Additionally, increasing research and development are contributing to market growth. For instance, in December 2021, Novartis reported the introduction of T-Charge, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. Furthermore, in January 2022, Bristol-Myers Squibb Company reported that Japan's Ministry of Health, Labour and Welfare approved Abecma (idecabtagene violence), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma. Such developments drive the demand for CAR T-cell therapies, thereby contributing to market growth.
Hence, due to the rise in cancer cases, and the increase in research and development in CAR T- cell therapy, the studied market is expected to witness growth over the forecast period. However, the high cost of developing CAR T-cell therapy is a major factor hindering market growth.
Car T-Cell Therapy Market Trends
This section covers the major market trends shaping the Car T-Cell Therapy Market according to our research experts:
Multiple Myeloma is Expected to Observe a Significant Growth Over the Forecast Period
Multiple myeloma is cancer that forms in a type of white blood cell called a plasma cell. It is also known as Kahler's disease. The major factors fueling the market growth are the increasing burden of multiple myeloma, increasing research and development, and the implementation of strategic initiatives by the market players. For instance, as per Cancer Australia, In 2022, it is estimated that 2,625 new cases of multiple myeloma were diagnosed in Australia (1,540 males and 1,085 females). According to the same source, in 2022, it is estimated that a person has a 1 in 111 (or 0.90%) risk of being diagnosed with multiple myeloma by the age of 85 (1 in 94 or 1.1% for males and 1 in 135 or 0.74% for females).
The increasing number of approvals is also contributing to the market growth. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson reported the United States Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Similarly, in October 2022, the FDA granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Thus, the market is expected to witness significant growth over the forecast period due to the above developments.
Hence, due to the rise in multiple myeloma cases, and the increase in product launches, the studied segment is expected to witness growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America is expected to witness growth in the studied market owing to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.
For instance, according to the American Cancer Society 2023 Cancer Statistics, the new number of cancer cases is estimated to be 1,958,310 in the United States in 2023. This estimation includes 1,010,310 number of males and 948,000 cases of females. Such a high number of cancer cases indicates the rising demand for CAR T-cell therapy in the country, thereby contributing to market growth. Additionally, several strategic initiatives the players implement contribute to market growth. For instance, in April 2022, Kite, a Gilead Company, reported the FDA-approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite's FDA-approved CAR T-cell therapy to treat blood cancer. Furthermore, clinical studies showing promising results in CAR T-cell therapies across the region are anticipated to increase the market demand. For instance, as per the June 2022 update from uOttawa, one of the first made-in-Canada CAR-T cell therapy for cancer showed promising results in the clinical trial. The trial is called Canadian-Led Immunotherapies in Cancer-01 (CLIC-01). It uses a different kind of cell manufacturing that opens the door to less expensive and more equitable treatment.
Moreover, the growing number of investments contributes to market growth. For instance, in June 2021, Blackstone reported that funds managed by Blackstone Life Sciences had committed USD 250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company.
Hence, due to the rise in cancer cases and the increase in clinical studies in CAR T -Cell therapies, North America is expected to witness growth over the forecast period.
Car T-Cell Therapy Industry Overview
The CAR T-Cell therapy market is moderately competitive with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson, and Sorrento Therapeutics, Inc., among other players.
Car T-Cell Therapy Market Leaders
Novartis AG
Bristol-Myers Squibb Company
Johnson & Johnson
Sorrento Therapeutics, Inc.
Gilead Sciences, Inc. (Kite Pharma)
*Disclaimer: Major Players sorted in no particular order
Car T-Cell Therapy Market News
- June 2022: Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
- April 2022: Kite, a Gilead Company, received FDA approval for Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
Car T-Cell Therapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer Worldwide
4.2.2 Increasing Invesment and Research and Development to Develop CAR T-Cell Therapy
4.3 Market Restraints
4.3.1 High Cost of Developing CAR T-Cell Therapy
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type
5.1.1 Abecma
5.1.2 Breyanzi
5.1.3 Kymriah
5.1.4 Tecartus
5.1.5 Yescarta
5.1.6 Others
5.2 By Application
5.2.1 Leukemia
5.2.2 Lymphoma
5.2.3 Multiple Myeloma
5.2.4 Autoimmune Disorders
5.2.5 Other Application
5.3 By End User
5.3.1 Hospitals
5.3.2 Cancer Care Treatment Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bristol-Myers Squibb Company
6.1.3 Gilead Sciences, Inc. (Kite Pharma)
6.1.4 Johnson & Johnson
6.1.5 Eli Lilly and Company
6.1.6 Sorrento Therapeutics, Inc.
6.1.7 ACROBiosystems
6.1.8 Celyad Oncology
6.1.9 Sangamo Therapeutics, Inc.
6.1.10 Servier Laboratories
6.1.11 Noile-Immune Biotech, Inc.
6.1.12 Miltenyi Biotec
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Car T-Cell Therapy Industry Segmentation
As per the scope of the report, chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy. It modifies a person's immune system, making it more effective at fighting chronic disorders such as cancer and other disorders. The CAR T-Cell Therapy Market is Segmented by Types (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Applications (Leukemia, Lymphoma, Multiple Myeloma, and Autoimmune Disorders, and Other Applications), End Users (Hospitals, Cancer Care Treatment Centers) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Type | |
| Abecma | |
| Breyanzi | |
| Kymriah | |
| Tecartus | |
| Yescarta | |
| Others |
| By Application | |
| Leukemia | |
| Lymphoma | |
| Multiple Myeloma | |
| Autoimmune Disorders | |
| Other Application |
| By End User | |
| Hospitals | |
| Cancer Care Treatment Centers | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Car T-Cell Therapy Market Research FAQs
What is the current Global CAR T-Cell Therapy Market size?
The Global CAR T-Cell Therapy Market is projected to register a CAGR of 30% during the forecast period (2024-2029)
Who are the key players in Global CAR T-Cell Therapy Market?
Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Sorrento Therapeutics, Inc. and Gilead Sciences, Inc. (Kite Pharma) are the major companies operating in the Global CAR T-Cell Therapy Market.
Which is the fastest growing region in Global CAR T-Cell Therapy Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global CAR T-Cell Therapy Market?
In 2024, the North America accounts for the largest market share in Global CAR T-Cell Therapy Market.
What years does this Global CAR T-Cell Therapy Market cover?
The report covers the Global CAR T-Cell Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global CAR T-Cell Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global CAR T-Cell Therapy Industry Report
Statistics for the 2024 Global CAR T-Cell Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global CAR T-Cell Therapy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
